Marker Therapeutics (NASDAQ:MRKR) Shares Down 3.3% – Time to Sell?

Marker Therapeutics, Inc. (NASDAQ:MRKR)’s stock price traded down 3.3% during mid-day trading on Monday . The stock traded as low as $1.45 and last traded at $1.46. 34,640 shares changed hands during mid-day trading, a decline of 47% from the average daily volume of 65,132 shares. The stock had previously closed at $1.51.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on MRKR shares. HC Wainwright reaffirmed a “buy” rating on shares of Marker Therapeutics in a report on Wednesday, May 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Marker Therapeutics in a report on Wednesday, June 24th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $10.00.

Marker Therapeutics Stock Performance

The firm has a market cap of $23.67 million, a price-to-earnings ratio of -2.33 and a beta of 1.45. The business’s 50-day moving average is $1.44 and its 200-day moving average is $1.52.

Marker Therapeutics (NASDAQ:MRKR) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.02. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 73.29%. The firm had revenue of $0.75 million for the quarter, compared to analysts’ expectations of $0.78 million. Equities research analysts expect that Marker Therapeutics, Inc. will post -1.17 EPS for the current fiscal year.

Hedge Funds Weigh In On Marker Therapeutics

Several institutional investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new stake in shares of Marker Therapeutics in the third quarter valued at $25,000. Two Sigma Investments LP acquired a new stake in Marker Therapeutics in the 3rd quarter valued at about $33,000. Jane Street Group LLC acquired a new position in shares of Marker Therapeutics during the second quarter worth approximately $33,000. Boyer Financial Services Inc. acquired a new position in shares of Marker Therapeutics during the fourth quarter worth approximately $57,000. Finally, XTX Topco Ltd grew its stake in shares of Marker Therapeutics by 166.6% during the fourth quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock valued at $86,000 after purchasing an additional 36,269 shares during the last quarter. Institutional investors own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.